Literature DB >> 10333491

Stable expression of protective protein/cathepsin A-green fluorescent protein fusion genes in a fibroblastic cell line from a galactosialidosis patient. Model system for revealing the intracellular transport of normal and mutated lysosomal enzymes.

Y Naganawa1, K Itoh, M Shimmoto, S Kamei, K Takiguchi, H Doi, H Sakuraba.   

Abstract

Fibroblastic cell lines derived from a galactosialidosis patient, stably expressing the chimaeric green fluorescent protein variant (EGFP) gene fused to the wild-type and mutant human lysosomal protective protein/cathepsin A (PPCA) cDNA, were first established as a model system for revealing the sorting and processing of lysosomal enzymes and for investigating the molecular bases of their deficiencies. In the cell line expressing the wild-type PPCA-EGFP chimaera gene (EGFP-PPwild), an 81 kDa form (27 kDa EGFP fused to the C-terminus of the 54 kDa PPCA precursor) was produced, then processed into the mature 32/20 kDa two-chain form free of the EGFP domain. The intracellular cathepsin A, alpha-N-acetylneuraminidase and beta-galactosidase activities, which are deficient in the parent fibroblastic cells, could also be significantly restored in the cells. In contrast with the uniform and strong fluorescence throughout the cytoplasm and nucleus in the mock-cell line expressing only EGFP cDNA, weak reticular and punctate fluorescence was distributed throughout the EGFP-PPwild cell line. Bafilomycin A1, a potent inhibitor of vacuolar ATPase and intracellular acidification, induced the distribution of Golgi-like perinuclear fluorescence throughout the living and fixed cells, in which only the 81 kDa product was detected. After removal of the agent, time-dependent transport of the chimaeric protein from the Golgi apparatus to the prelysosomal structure in living cells was monitored with a confocal laser scanning microscope system. Leupeptin caused the distribution of lysosome-like granular fluorescence throughout the cytoplasm in the fixed cells, although it was hardly observed in living cells. The latter agent also dose-dependently induced an increase in the intracellular amount of the 81 kDa product containing the EGFP domain and inhibited the restoration of cathepsin A activity in the EGFP-PPwild cells after the removal of bafilomycin A1. In parallel, both the mature two-chain form and PPCA function disappeared. These results suggested that the chimaera gene product was transported to acidic compartments (endosomes/lysosomes), where proteolytic processing of the PPCA precursor/zymogen, quenching of the fluorescence, and random degradation of the EGFP portion occurred. A cell line stably expressing a chimaeric gene with a mutant PPCA cDNA containing an A1184-->G (Y395C) mutation, commonly detected in Japanese severe early-infantile type of galactosialidosis patients, showed an endoplasmic reticulum (ER)-like reticular fluorescence pattern. The PPCA-immunoreactive gene product was hardly detected in this cell line. The mutant chimaeric product was suggested to be degraded rapidly in the ER before transport to post-ER compartments. A cell line expressing the chimaeric gene with a T746-->A (Y249N) PPCA mutation exhibited both ER-like reticular and granular fluorescence on the reticular structure that was stronger than that in the EGFP-PPwild cells. Some of them contained large fluorescent inclusion-body-like structures. The ineffectiveness of transport inhibitors in the distribution changes in the two mutant chimaeric proteins suggested that they were not delivered to acidic compartments. Therefore this expression system can possibly be applied to the direct analysis of the sorting defects of mutant gene products in living cells and will be useful for the molecular investigation of lysosomal diseases, including galactosialidosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10333491      PMCID: PMC1220273          DOI: 10.1042/bj3400467

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  28 in total

1.  Molecular form and subcellular distribution of acid beta-galactosidase in fibroblasts from patients with GM1 gangliosidosis, Morquio B disease and galactosialidosis.

Authors:  N Takiyama; K Itoh; M Shimmoto; J Nishimoto; K Inui; H Sakuraba; Y Suzuki
Journal:  Brain Dev       Date:  1997-03       Impact factor: 1.961

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  Molecular and biochemical analysis of protective protein/cathepsin A mutations: correlation with clinical severity in galactosialidosis.

Authors:  X Y Zhou; A van der Spoel; R Rottier; G Hale; R Willemsen; G T Berry; P Strisciuglio; A Morrone; E Zammarchi; G Andria; A d'Azzo
Journal:  Hum Mol Genet       Date:  1996-12       Impact factor: 6.150

4.  Characterization of human lysosomal neuraminidase defines the molecular basis of the metabolic storage disorder sialidosis.

Authors:  E Bonten; A van der Spoel; M Fornerod; G Grosveld; A d'Azzo
Journal:  Genes Dev       Date:  1996-12-15       Impact factor: 11.361

5.  The atomic model of the human protective protein/cathepsin A suggests a structural basis for galactosialidosis.

Authors:  G Rudenko; E Bonten; W G Hol; A d'Azzo
Journal:  Proc Natl Acad Sci U S A       Date:  1998-01-20       Impact factor: 11.205

6.  Fetal diagnosis of galactosialidosis (protective protein/cathepsin A deficiency).

Authors:  K Itoh; N Miharu; K Ohama; N Mizoguchi; N Sakura; H Sakuraba
Journal:  Clin Chim Acta       Date:  1997-10-31       Impact factor: 3.786

7.  FACS-optimized mutants of the green fluorescent protein (GFP).

Authors:  B P Cormack; R H Valdivia; S Falkow
Journal:  Gene       Date:  1996       Impact factor: 3.688

8.  Galactosialidosis: a direct evidence that a 46-kilodalton protein restores deficient enzyme activities in fibroblasts.

Authors:  E Nanba; A Tsuji; K Omura; Y Suzuki
Journal:  Biochem Biophys Res Commun       Date:  1987-04-14       Impact factor: 3.575

9.  Molecular defect in combined beta-galactosidase and neuraminidase deficiency in man.

Authors:  A D'Azzo; A Hoogeveen; A J Reuser; D Robinson; H Galjaard
Journal:  Proc Natl Acad Sci U S A       Date:  1982-08       Impact factor: 11.205

10.  Galactosialidosis (beta-galactosidase-neuraminidase deficiency): a possible role of serine-thiol proteases in the degradation of beta-galactosidase molecules.

Authors:  H Sakuraba; T Aoyagi; Y Suzuki
Journal:  Clin Chim Acta       Date:  1982-11-10       Impact factor: 3.786

View more
  2 in total

1.  Peptides presented by HLA-DR molecules in synovia of patients with rheumatoid arthritis or antibiotic-refractory Lyme arthritis.

Authors:  Robert J Seward; Elise E Drouin; Allen C Steere; Catherine E Costello
Journal:  Mol Cell Proteomics       Date:  2010-11-16       Impact factor: 5.911

2.  A pro-cathepsin L mutant is a luminal substrate for endoplasmic-reticulum-associated degradation in C. elegans.

Authors:  Mark T Miedel; Nathan J Graf; Kate E Stephen; Olivia S Long; Stephen C Pak; David H Perlmutter; Gary A Silverman; Cliff J Luke
Journal:  PLoS One       Date:  2012-07-02       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.